| Hemophilia A
Altuviiio vs Xyntha
Side-by-side clinical, coverage, and cost comparison for hemophilia a.Deep comparison between: Altuviiio vs Xyntha with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXyntha has a higher rate of injection site reactions vs Altuviiio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xyntha but not Altuviiio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Altuviiio
Xyntha
At A Glance
IV infusion
Once weekly
Recombinant factor VIII
IV infusion
3 times weekly (prophylaxis)
Factor VIII replacement
Indications
- Hemophilia A
- Hemophilia A
Dosing
Hemophilia A - Routine Prophylaxis 50 IU/kg IV once weekly for adults and children.
Hemophilia A - On-demand (Minor and Moderate Bleeding) Single dose of 50 IU/kg IV; a lower dose of 30 IU/kg may be used for bleeds occurring within 2 to 3 days after a prophylactic dose; additional doses of 30 or 50 IU/kg every 2 to 3 days may be considered.
Hemophilia A - On-demand (Major Bleeding) Single dose of 50 IU/kg IV; additional doses of 30 or 50 IU/kg every 2 to 3 days may be considered.
Hemophilia A - Perioperative (Minor Surgery) Pre-operative: single dose of 50 IU/kg IV; post-operative: an additional dose of 30 or 50 IU/kg after 2 to 3 days may be considered.
Hemophilia A - Perioperative (Major Surgery) Pre-operative: single dose of 50 IU/kg IV; post-operative: additional doses of 30 or 50 IU/kg every 2 to 3 days as clinically needed.
Hemophilia A - On-demand / Bleeding episodes Dose calculated as body weight (kg) x desired FVIII rise (IU/dL) x 0.5; minor bleeds: 20-40 IU/dL target every 12-24 hrs; moderate: 30-60 IU/dL every 12-24 hrs; major: 60-100 IU/dL every 8-24 hrs; IV infusion.
Hemophilia A - Perioperative management Minor surgery: 30-60 IU/dL target every 12-24 hrs for 3-4 days; major surgery: 60-100 IU/dL target every 8-24 hrs until adequate local hemostasis achieved; IV infusion.
Hemophilia A - Routine prophylaxis Adults and adolescents (>=12 years): 30 IU/kg 3 times weekly IV; adjust dose or frequency based on clinical response.
Contraindications
- Severe hypersensitivity reactions, including anaphylaxis, to ALTUVIIIO or any of its excipients
- Life-threatening immediate hypersensitivity reactions, including anaphylaxis, to XYNTHA or its components, including hamster proteins
Adverse Reactions
Most common (>10%) Headache, arthralgia (adults and adolescents); pyrexia (children below 12 years)
Serious Thromboembolic events (1% of patients in long-term extension, in patients with pre-existing risk factors)
Postmarketing Factor VIII inhibitor development, hypersensitivity reactions including anaphylaxis
Most common (>=10%) Headache, arthralgia, pyrexia, cough
Postmarketing Inadequate therapeutic response
Pharmacology
Recombinant FVIII Fc-VWF-XTEN fusion protein that temporarily replaces missing coagulation factor VIII to restore hemostasis in hemophilia A; half-life is extended 3- to 4-fold over standard FVIII products through Fc-FcRn recycling, VWF D'D3 domain shielding from endogenous VWF, and XTEN-mediated reduction in clearance.
XYNTHA temporarily replaces missing clotting factor VIII needed for effective hemostasis; treatment normalizes activated partial thromboplastin time (aPTT) over the effective dosing period.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Altuviiio
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Xyntha
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Altuviiio
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Xyntha
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Altuviiio
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Xyntha
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AltuviiioView full Altuviiio profile
XynthaView full Xyntha profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.